Cargando…

The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)

Malignant pleural mesothelioma (MPM) is an aggressive malignancy with limited effective treatment options. Focal adhesion kinase (FAK) inhibitors have been shown to efficiently suppress MPM cell growth initially, with limited utility in the current clinical setting. In this study, we utilised a larg...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuen, Man Lee, Zhuang, Ling, Rath, Emma M., Yu, Takun, Johnson, Ben, Sarun, Kadir Harun, Wang, Yiwei, Kao, Steven, Linton, Anthony, Clarke, Candice Julie, McCaughan, Brian C., Takahashi, Ken, Lee, Kenneth, Cheng, Yuen Yee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508233/
https://www.ncbi.nlm.nih.gov/pubmed/34638565
http://dx.doi.org/10.3390/ijms221910225
_version_ 1784582047412518912
author Yuen, Man Lee
Zhuang, Ling
Rath, Emma M.
Yu, Takun
Johnson, Ben
Sarun, Kadir Harun
Wang, Yiwei
Kao, Steven
Linton, Anthony
Clarke, Candice Julie
McCaughan, Brian C.
Takahashi, Ken
Lee, Kenneth
Cheng, Yuen Yee
author_facet Yuen, Man Lee
Zhuang, Ling
Rath, Emma M.
Yu, Takun
Johnson, Ben
Sarun, Kadir Harun
Wang, Yiwei
Kao, Steven
Linton, Anthony
Clarke, Candice Julie
McCaughan, Brian C.
Takahashi, Ken
Lee, Kenneth
Cheng, Yuen Yee
author_sort Yuen, Man Lee
collection PubMed
description Malignant pleural mesothelioma (MPM) is an aggressive malignancy with limited effective treatment options. Focal adhesion kinase (FAK) inhibitors have been shown to efficiently suppress MPM cell growth initially, with limited utility in the current clinical setting. In this study, we utilised a large collection of MPM cell lines and MPM tissue samples to study the role of E-cadherin (CDH1) and microRNA on the efficacy of FAK inhibitors in MPM. The immunohistochemistry (IHC) results showed that the majority of MPM FFPE samples exhibited either the absence of, or very low, E-cadherin protein expression in MPM tissue. We showed that MPM cells with high CDH1 mRNA levels exhibited resistance to the FAK inhibitor PND-1186. In summary, MPM cells that did not express CDH1 mRNA were sensitive to PND-1186, and MPM cells that retained CDH1 mRNA were resistant. A cell cycle analysis showed that PND-1186 induced cell cycle disruption by inducing the G2/M arrest of MPM cells. A protein−protein interaction study showed that EGFR is linked to the FAK pathway, and a target scan of the microRNAs revealed that microRNAs (miR-17, miR221, miR-222, miR137, and miR148) interact with EGFR 3′UTR. Transfection of MPM cells with these microRNAs sensitised the CHD1-expressing FAK-inhibitor-resistant MPM cells to the FAK inhibitor.
format Online
Article
Text
id pubmed-8508233
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85082332021-10-13 The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM) Yuen, Man Lee Zhuang, Ling Rath, Emma M. Yu, Takun Johnson, Ben Sarun, Kadir Harun Wang, Yiwei Kao, Steven Linton, Anthony Clarke, Candice Julie McCaughan, Brian C. Takahashi, Ken Lee, Kenneth Cheng, Yuen Yee Int J Mol Sci Article Malignant pleural mesothelioma (MPM) is an aggressive malignancy with limited effective treatment options. Focal adhesion kinase (FAK) inhibitors have been shown to efficiently suppress MPM cell growth initially, with limited utility in the current clinical setting. In this study, we utilised a large collection of MPM cell lines and MPM tissue samples to study the role of E-cadherin (CDH1) and microRNA on the efficacy of FAK inhibitors in MPM. The immunohistochemistry (IHC) results showed that the majority of MPM FFPE samples exhibited either the absence of, or very low, E-cadherin protein expression in MPM tissue. We showed that MPM cells with high CDH1 mRNA levels exhibited resistance to the FAK inhibitor PND-1186. In summary, MPM cells that did not express CDH1 mRNA were sensitive to PND-1186, and MPM cells that retained CDH1 mRNA were resistant. A cell cycle analysis showed that PND-1186 induced cell cycle disruption by inducing the G2/M arrest of MPM cells. A protein−protein interaction study showed that EGFR is linked to the FAK pathway, and a target scan of the microRNAs revealed that microRNAs (miR-17, miR221, miR-222, miR137, and miR148) interact with EGFR 3′UTR. Transfection of MPM cells with these microRNAs sensitised the CHD1-expressing FAK-inhibitor-resistant MPM cells to the FAK inhibitor. MDPI 2021-09-23 /pmc/articles/PMC8508233/ /pubmed/34638565 http://dx.doi.org/10.3390/ijms221910225 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yuen, Man Lee
Zhuang, Ling
Rath, Emma M.
Yu, Takun
Johnson, Ben
Sarun, Kadir Harun
Wang, Yiwei
Kao, Steven
Linton, Anthony
Clarke, Candice Julie
McCaughan, Brian C.
Takahashi, Ken
Lee, Kenneth
Cheng, Yuen Yee
The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)
title The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)
title_full The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)
title_fullStr The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)
title_full_unstemmed The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)
title_short The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)
title_sort role of e-cadherin and microrna on fak inhibitor response in malignant pleural mesothelioma (mpm)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508233/
https://www.ncbi.nlm.nih.gov/pubmed/34638565
http://dx.doi.org/10.3390/ijms221910225
work_keys_str_mv AT yuenmanlee theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT zhuangling theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT rathemmam theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT yutakun theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT johnsonben theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT sarunkadirharun theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT wangyiwei theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT kaosteven theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT lintonanthony theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT clarkecandicejulie theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT mccaughanbrianc theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT takahashiken theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT leekenneth theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT chengyuenyee theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT yuenmanlee roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT zhuangling roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT rathemmam roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT yutakun roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT johnsonben roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT sarunkadirharun roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT wangyiwei roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT kaosteven roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT lintonanthony roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT clarkecandicejulie roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT mccaughanbrianc roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT takahashiken roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT leekenneth roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm
AT chengyuenyee roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm